180386-35-0 Usage
General Description
BOC-3-Carboxymethyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one is a complex chemical compound belonging to the category of organo-nitrogen compounds, specifically within azaspiro compounds. Its structure features a unique spirocyclic framework with a triazaspiro core. Despite no significant ongoing applications or extensive research, this chemical base is typically used in laboratory settings for experimental purposes, showing potential in the development of novel organo-nitrogen chemistry substrates. Owing to its complex structure and specific nomenclature, it contributes to the vast diversity in organic chemistry. Its potential implications and uses require further research and exploration.
Check Digit Verification of cas no
The CAS Registry Mumber 180386-35-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,0,3,8 and 6 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 180386-35:
(8*1)+(7*8)+(6*0)+(5*3)+(4*8)+(3*6)+(2*3)+(1*5)=140
140 % 10 = 0
So 180386-35-0 is a valid CAS Registry Number.
180386-35-0Relevant articles and documents
Synthesis and characterization of pseudopeptide bradykinin B2 receptor antagonists containing the 1,3,8-triazaspiro[4.5]decan-4-one ring system
Mavunkel, Babu J.,Lu, Zhijian,Goehring, R. Richard,Lu, Songfeng,Chakravarty, Sarvajit,Perumattam, John,Novotny, Elizabeth A.,Connolly, Maureen,Valentine, Heather,Kyle, Donald J.
, p. 3169 - 3173 (2007/10/03)
A series of pseudopeptides containing alkyl-, cycloalkyl-, aryl-, and aralkyl-substituted 1,3,8-triazaspiro[4.5]decan-4-one-3-acetic acids as amino acid surrogates to replace the Pro2-Pro3-Gly4-Phe5 section of the peptide bradykinin B2 receptor antagonist [Pro3, Phe5]HOE 140 (D-Arg0-Arg1- Pro2-Pro3-Gly4-Phe5-Ser6-D-Tic7-Oic8-Arg9) were prepared. These psuedopeptides were examined in vitro for their B2 receptor affinities as well as for their ability to block bradykinin mediated actions in vivo. Two compounds in particular, NPC 18521 (I) and NPC 18688 (V) were quite potent in these latter assays, indicating that a significant portion of this prototypical second generation decapeptide antagonist can be replaced with a more compact nonpeptide molecule.
